An observational study in Crohn Disease, sponsored by Central Hospital, Nancy, France. Status unknown. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-08.
Sponsored by Central Hospital, Nancy, France · Observational
Crohn's disease is a inflammatory bowel disease evolving towards the destruction of the intestinal wall resulting in stenosing or perforating complications (fistulas, abscesses).
The treatment of perforating Crohn's disease is not codified.
The old dogmas leading to surgery after failure of medical treatment have recently been overturned, particularly since the advent of anti-TNFs.
Biotherapies now have a central place, including for complicated forms. Previous studies have already looked at the usefulness of anti-TNFs in stenosing forms, or concerning ano-perineal lesions, but what about digestive fistulas.
Indeed, data are scarce, especially in paediatrics.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 40 is below the median of 162 across 608 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug
Also known as: Adalimumab, Ustékinumab
Surgery
Also known as: Resection
No fistula
Complete remission = clinical remission and biological remission and iconographic remission: * clinical remission (asymptomatic at 12 months from inclusion). * biological remission (normalization of biological parameters 12 months after inclusion). * iconographic remission (no active lesion, and in particular no visualized fistula)
Time frame: 12 month
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France